{"id":834184,"date":"2025-04-04T16:48:03","date_gmt":"2025-04-04T20:48:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/"},"modified":"2025-04-04T16:48:03","modified_gmt":"2025-04-04T20:48:03","slug":"aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/","title":{"rendered":"AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">OCALA, Fla., April  04, 2025  (GLOBE NEWSWIRE) &#8212; AIM ImmunoTech Inc. (\u201cAIM\u201d or the \u201cCompany\u201d) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, reported that on April 4, 2025, it received notification from NYSE Regulation of the NYSE American LLC (the \u201cNYSE American\u201d or the \u201cExchange\u201d) that it had suspended trading of the Company\u2019s common stock and of its determination to commence delisting proceedings of the Company\u2019s common stock from the Exchange pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company\u2019s common stock. The Company plans to appeal the determination to the Exchange\u2019s Listing Qualifications Panel, although there can be no assurance that any such appeal will be successful.<\/p>\n<p align=\"justify\">The Company\u2019s common stock is expected to begin trading on the Pink Open Market on April 7, 2025.<\/p>\n<p align=\"justify\">Additional details are included in, and the description above is qualified in its entirety by, AIM\u2019s Current Report on Form 8-K filed with the SEC on April 4, 2025, which will be made available under \u201cInvestors\u201d \u2013 \u201cSEC Filings\u201d at aimimmuno.com.<\/p>\n<p align=\"justify\">\n        <strong> About AIM ImmunoTech Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company\u2019s lead product is a first-in-class investigational drug called Ampligen<sup>\u00ae<\/sup> (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.<\/p>\n<p align=\"justify\">For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JMUts2Zp2HM5Iz3RigOpZplsc1i2qbdWzeILSHVzjXHIR4ANue9_GMTatV2Gq8uJB9XfLhZHO8ZPIGvAqEhrIA==\" rel=\"nofollow\" target=\"_blank\">aimimmuno.com<\/a>\u00a0and connect with the Company on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IqNq3oJ7JqysRMb1-_1lm6w2XVoBEujhTes7tdg9r9GhXDO--c_Q3IdS5wqtSUr6MQS5kH6-diG9hjWfbDzSvQ==\" rel=\"nofollow\" target=\"_blank\">X<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2qd_pB-EI2YhluKKbjmzVGeAU7ZJqgJE6RzBJLlVxoQ4v4lMbnE3N_0LyA93uJ-n-D6M0hMFGA78al9KRolX9xLS0hglTqzjVF_VcFJ09oaf53jiGaRbeLzHjvTSIKhw\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F7OG7UbgT_P6z40uemEElLiCYFVIV1o9Ez3-mA_5zZTyX20ZRKE7FC6CLe9_Pgs7vZMGSX_hlZTLQJKPvE4NfGfY0FZ2YSjc6vWtnaNwiL4=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management\u2019s current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d or \u201cwould\u201d and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company\u2019s intention to regain compliance with the listing requirements of the NYSE American and its ability to do so. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained herein speak only as of the date hereof, and the Company assumes no\u00a0obligation to update any forward-looking statements, whether as a result of new information, subsequent events or otherwise, except as required by law.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzM5NyM2ODUyNDM1IzIwMjMxNjQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTQ4YzIzZjgtOGIwNC00ZTYwLTg0N2QtZWY1MGM1NWM1YWMxLTEwMzQ3MzUtMjAyNS0wNC0wNC1lbg==\/tiny\/AIM-ImmunoTech-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor Contact:\r\nJTC Team, LLC\r\nJenene Thomas\r\n908.824.0775\r\nAIM@jtcir.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>OCALA, Fla., April 04, 2025 (GLOBE NEWSWIRE) &#8212; AIM ImmunoTech Inc. (\u201cAIM\u201d or the \u201cCompany\u201d) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, reported that on April 4, 2025, it received notification from NYSE Regulation of the NYSE American LLC (the \u201cNYSE American\u201d or the \u201cExchange\u201d) that it had suspended trading of the Company\u2019s common stock and of its determination to commence delisting proceedings of the Company\u2019s common stock from the Exchange pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company\u2019s common stock. The Company plans to appeal the determination to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-834184","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"OCALA, Fla., April 04, 2025 (GLOBE NEWSWIRE) &#8212; AIM ImmunoTech Inc. (\u201cAIM\u201d or the \u201cCompany\u201d) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, reported that on April 4, 2025, it received notification from NYSE Regulation of the NYSE American LLC (the \u201cNYSE American\u201d or the \u201cExchange\u201d) that it had suspended trading of the Company\u2019s common stock and of its determination to commence delisting proceedings of the Company\u2019s common stock from the Exchange pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company\u2019s common stock. The Company plans to appeal the determination to &hellip; Continue reading &quot;AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-04T20:48:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzM5NyM2ODUyNDM1IzIwMjMxNjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal\",\"datePublished\":\"2025-04-04T20:48:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\\\/\"},\"wordCount\":529,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzM5NyM2ODUyNDM1IzIwMjMxNjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\\\/\",\"name\":\"AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzM5NyM2ODUyNDM1IzIwMjMxNjQ=\",\"datePublished\":\"2025-04-04T20:48:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzM5NyM2ODUyNDM1IzIwMjMxNjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzM5NyM2ODUyNDM1IzIwMjMxNjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/","og_locale":"en_US","og_type":"article","og_title":"AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - Market Newsdesk","og_description":"OCALA, Fla., April 04, 2025 (GLOBE NEWSWIRE) &#8212; AIM ImmunoTech Inc. (\u201cAIM\u201d or the \u201cCompany\u201d) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, reported that on April 4, 2025, it received notification from NYSE Regulation of the NYSE American LLC (the \u201cNYSE American\u201d or the \u201cExchange\u201d) that it had suspended trading of the Company\u2019s common stock and of its determination to commence delisting proceedings of the Company\u2019s common stock from the Exchange pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company\u2019s common stock. The Company plans to appeal the determination to &hellip; Continue reading \"AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-04T20:48:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzM5NyM2ODUyNDM1IzIwMjMxNjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal","datePublished":"2025-04-04T20:48:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/"},"wordCount":529,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzM5NyM2ODUyNDM1IzIwMjMxNjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/","name":"AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzM5NyM2ODUyNDM1IzIwMjMxNjQ=","datePublished":"2025-04-04T20:48:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzM5NyM2ODUyNDM1IzIwMjMxNjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzM5NyM2ODUyNDM1IzIwMjMxNjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-nyse-american-notice-of-delisting-and-appeal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/834184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=834184"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/834184\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=834184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=834184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=834184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}